IVIG - West Nile Encephalitis: Safety and Efficacy

A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis

This study will look at the safety and effectiveness of an experimental medication containing antibodies (Omr-IgG-am™) in people with West Nile Virus (WNV) who already have brain and/or spinal cord inflammation or who are at high risk of developing these problems because they have weak immune systems. WNV can cause problems such as headaches, fever, muscle weakness, coma, and death. Study investigators believe people who are not able to fight infection well may be at risk for developing neurologic problems (having to do with the brain, spinal cord, nerves, and muscles) if they get WNV infection. Up to 110 subjects, 18 years or older, will participate for about 3 months and will receive either Omr-IgG-am™, Polygam® S/D, or placebo given through a small tube placed in a blood vessel in the arm. Hospitalization, up to 5 additional study visits, blood sample collection, MRI pictures of the brain and spinal cord, and neurological, muscle, and heart activity tests are also required.

Study Overview

Status

Completed

Conditions

Detailed Description

The purpose of this study is to assess whether Omr-IgG-am™, an intravenous immunoglobulin (IVIg) containing antibodies specific for West Nile virus (WNV), is safe and well-tolerated in patients with suspected or laboratory diagnosed WNV disease. An initial estimation of efficacy will also be made. This Phase I/II study will enroll hospitalized adults with a presumptive diagnosis of West Nile encephalitis and/or myelitis or those with a positive laboratory test for diagnosis of WNV infection who are at high risk for progressing to severe neurologic disease based on age or immunosuppression. Patients will be randomized in blocks of five to receive either Omr-IgGam ™, Polygam® S/D (IVIG containing minimal anti-WNV antibodies) or normal saline in a ratio of 3:1:1. Patients and investigators will be blinded to treatment assignments. Patients will receive a single intravenous dose of study medication or one of two placebos. The study participants will receive 0.5 grams/kg of Omr-IgG-am™ or Polygam® S/D or a comparable volume of normal saline. All patients will be followed for safety, natural history endpoints, and efficacy. A subset of patients will have pharmacokinetic measurements of specific anti-WNV antibodies assessed following treatment. The primary endpoints are safety and tolerability following Omr-IgG-am™ administration. Secondary endpoints include pharmacokinetics of specific anti-WNV antibodies, mortality in confirmed WNV positive patients, and the combination of mortality and functional status at three months in both confirmed WNV-infected patients and all patients by intention to treat. This combined endpoint will be measured using four standardized measures of cognitive and functional status: the Barthel Index; the Modified Rankin Scale; the Glasgow Outcome Score; and the Modified Mini-Mental Status Examination. A comparison of outcomes will be made for the group receiving Omr-IgG-am™ versus those receiving either placebo, and between the two placebo groups. Other secondary endpoints include the proportion of patients in each group returning to pre-morbid baseline and each subject's improvement at 3 months as compared to that subject's worst (of any previous) evaluation. Natural history endpoints will also be assessed. They will include the duration of intensive care unit and hospital stay, development and persistence of WNV-specific IgG and IgM antibodies, combined functional score and mortality at 3 months between the group with encephalitis and/or myelitis at baseline versus the group with a positive WNV test only, outcomes in patients treated late in coma and correlation of outcome with time-to-treatment following symptom onset.

Study Type

Interventional

Enrollment (Actual)

62

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T2N4N
        • University of Calgary
      • Edmonton, Alberta, Canada, T6G 2B7
        • University of Alberta
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0W3
        • University of Manitoba
    • Alabama
      • Birmingham, Alabama, United States, 35294-2050
        • University of Alabama at Birmingham
      • Mobile, Alabama, United States, 36617
        • University of South Alabama Medical Center
    • Arizona
      • Phoenix, Arizona, United States, 85054
        • Mayo Clinic Hospital
      • Phoenix, Arizona, United States, 85013
        • St. Joseph's Hospital and Medical Center
      • Tucson, Arizona, United States, 85724
        • University of Arizona Health Sciences Center
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • University of Arkansas
    • California
      • Chico, California, United States, 95926
        • Enloe Medical Center
      • Daly City, California, United States, 94015
        • Seton Medical Center
      • Duarte, California, United States, 91010
        • City of Hope National Medical Center
      • Harbor City, California, United States, 90710
        • Kaiser Permanente South Bay Medical Center
      • Los Angeles, California, United States, 90033
        • University of Southern California
      • Orange, California, United States, 92868-3298
        • University of California Irvine
      • Sacramento, California, United States, 95817
        • University of California Davis Medical Center
      • San Francisco, California, United States, 94115
        • California Pacific Medical Center
      • San Francisco, California, United States, 94114
        • University of California San Francisco
      • Santa Rosa, California, United States, 95403
        • Santa Rosa Kaiser Medical
    • Colorado
      • Denver, Colorado, United States, 80262
        • University of Colorado
      • Denver, Colorado, United States, 80218
        • Exempla St. Joseph Hospital
    • District of Columbia
      • Washington, District of Columbia, United States, 20037
        • George Washington University Medical Center
    • Idaho
      • Idaho Falls, Idaho, United States, 83404
        • Idaho Falls Infectious Diseases, PLLC
    • Illinois
      • Maywood, Illinois, United States, 60153
        • Loyola University
    • Indiana
      • Indianapolis, Indiana, United States, 46202-5124
        • Indiana University
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • University of Kansas Medical Center
      • Wichita, Kansas, United States, 67214
        • Via Christi Regional Medical Center
    • Kentucky
      • Lexington, Kentucky, United States, 40536-0084
        • University of Kentucky
    • Louisiana
      • New Orleans, Louisiana, United States, 70112
        • Tulane University
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins University
      • Bethesda, Maryland, United States, 20892-1662
        • National Institutes of Health
    • Michigan
      • Ann Arbor, Michigan, United States, 48105
        • University of Michigan
      • Detroit, Michigan, United States, 48201
        • Wayne State University
    • Missouri
      • Saint Louis, Missouri, United States, 63110-1093
        • Washington University in St. Louis
      • St. Louis, Missouri, United States, 63110
        • Saint Louis University
    • Montana
      • Butte, Montana, United States, 59701
        • Mercury Street Medical Group
      • Missoula, Montana, United States, 59802
        • Infectious Disease Specialists, PC
    • Nebraska
      • Broken Bow, Nebraska, United States, 68822
        • Central Nebraska Medical Clinic
      • McCook, Nebraska, United States, 69001
        • McCook Clinic, PC
      • North Platte, Nebraska, United States, 69101
        • Great Plains Regional Medical Center
      • Omaha, Nebraska, United States, 68131
        • Creighton University
      • Omaha, Nebraska, United States, 68105
        • VA Medical Center - Omaha
      • Omaha, Nebraska, United States, 68198-7630
        • University of Nebraska Medical Center
    • New Jersey
      • Belleville, New Jersey, United States, 07109
        • Clara Maass Medical Center
    • New Mexico
      • Albuquerque, New Mexico, United States, 87106
        • University of New Mexico
    • New York
      • Flushing, New York, United States, 11355
        • Flushing Hospital Medical Center
    • North Dakota
      • Bismarck, North Dakota, United States, 58506
        • St. Alexius Medical Center
      • Fargo, North Dakota, United States, 58103
        • Dakota Clinic at Innovis
      • Fargo, North Dakota, United States, 58122
        • Meritcare Hospital
      • Minot, North Dakota, United States, 58701
        • Trinity Health - Hospital
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • University Hospital
      • Cleveland, Ohio, United States, 44106
        • University Hospitals of Cleveland
      • Toledo, Ohio, United States, 43614
        • University of Toledo
      • Wright-Patterson AFB, Ohio, United States, 45433
        • Wright-Patterson Medical Center
    • Oregon
      • Portland, Oregon, United States, 97210
        • Legacy Good Samaritan
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Lehigh Valley Hospital
      • West Reading, Pennsylvania, United States, 19611
        • The Reading Hospital and Medical Center
    • Rhode Island
      • Pawtucket, Rhode Island, United States, 02860
        • Memorial Hospital of RI
      • Providence, Rhode Island, United States, 02903
        • Rhode Island Hospital
    • South Dakota
      • Rapid City, South Dakota, United States, 57701
        • Infectious Disease Consultations - Rapid City
      • Sioux Falls, South Dakota, United States, 57105
        • Avera Research Institute
    • Tennessee
      • Nashville, Tennessee, United States, 37205
        • Vanderbilt University
    • Texas
      • Dallas, Texas, United States, 75390-8884
        • The University of Texas Southwestern Medical Center
      • Galveston, Texas, United States, 77555-0167
        • The University of Texas Medical Branch
      • Houston, Texas, United States, 77030
        • The University of Texas Health Science Center at Houston
      • San Antonio, Texas, United States, 78229-3900
        • The University of Texas Health Science Center
      • San Antonio, Texas, United States, 78236
        • Wilford Hall Medical Center
      • Tyler, Texas, United States, 75708
        • The University of Texas Health Science Center at Tyler
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • University of Virginia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

In order to participate in this clinical trial, all subjects (or legal representative) must provide written informed consent. Only patients meeting entry criteria will be enrolled. Eligible subjects must fall into one of two categories:

A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or myelitis as defined below:

New neurologic abnormality:

  • Asymmetric extremity weakness without sensory abnormality; or
  • Other neurologic abnormality (including altered level of consciousness, dysarthria and dysphagia) plus fever (subjective or objective) within the previous 4 days AND

CSF examination within the previous 96 hours showing:

  • Absence of organism on gram or fungal stain
  • White blood cell count greater than or equal to 4 per cubic mm corrected for significant red blood cell contamination.
  • Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose / plasma glucose greater than or equal to 0.4) Serum and CSF glucose levels should be obtained within 8 hours of each other for this calculation.

OR

B. Hospitalized patients, without encephalitis and/or myelitis as defined below, who meet the following criteria:

A positive IgM serology or PCR test for WNV in blood or cerebrospinal fluid, AND

Clinical illness compatible with WNV infection as described by occurrence of greater than or equal to 3 of the following findings during the preceding less than or equal to 10 days:

  • Diarrhea
  • Headache
  • Fever > 38º C
  • Nausea and/or vomiting
  • Myalgias and/or arthralgias
  • Nuchal rigidity
  • Macular or papular rash
  • New neurological abnormality AND

A risk factor for the development of WNV neurologic disease as defined by:

  • Age greater than or equal to 40 years, or
  • Age greater than or equal to 18 years plus immunosuppression, as defined by any of the following:

Hematologic malignancy; previous diagnosis of diabetes mellitus; chemotherapy within previous 4 weeks; stem cell transplant recipient or solid organ transplant recipient; taking immunosuppressive medications, including prednisone greater than or equal to 7.5 mg/day within the previous 4 weeks; history of human immunodeficiency virus (HIV) infection, congenital immunodeficiency syndrome (including common variable immunodeficiency)

Exclusion Criteria:

Unable to obtain valid informed consent History of intolerance (including anaphylaxis) to IVIg or related compounds Known history of IgA deficiency Known history of hypersensitivity to maltose

History of (or at time of study entry) hyperviscosity syndrome, such as but not limited to:

  • Waldenstrom's macroglobulinemia
  • Multiple myeloma
  • Total white blood cell count > 80,000/cubic mm
  • Hematocrit > 55%
  • Platelet count > 700,000/cubic mm Meets criteria of Class III or IV of the New York Heart Association Classification for congestive heart failure patients Serum creatinine > 2.5 mg/dL or requires dialysis Alternate explanation (as determined by the investigator) for clinical findings (such as structural brain lesion, cerebrovascular accident, or other infectious disease, including confirmed infections with other flaviviruses) Pregnant or breastfeeding (negative serum or urine pregnancy test within previous 72 hours if woman is not postmenopausal or has not been surgically sterilized) Investigator's opinion that patient would be unable to adhere to protocol requirements Receipt of ribavirin, interferon alpha, intravenous immunoglobulin, or any investigational drug for treatment of WNV or hepatitis within 15 days prior to study entry

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1
60 subjects to receive Omr-IgG-am.
Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
ACTIVE_COMPARATOR: 2
20 subjects to receive Polygam® S/D (IVIG).
Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
PLACEBO_COMPARATOR: 3
20 subjects to receive normal saline.
Normal Saline.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Safety (including all causes of mortality) in the test IVIg (Omr-IgG-am™) group versus the 2 placebo groups, as defined by the total number of serious adverse events regardless of relatedness to study drug administration.
Time Frame: Duration of study.
Duration of study.

Secondary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetics of specific anti-WNV antibodies as measured by ELISA and PRNT methods.
Time Frame: Baseline (pre-dose) blood sample collected immediately prior to the beginning of the infusion. After the infusion, additional blood samples collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 hr, and then at Day 5, Day 7, Day 14, Day 30, Day 60 and Day 90.
Baseline (pre-dose) blood sample collected immediately prior to the beginning of the infusion. After the infusion, additional blood samples collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 hr, and then at Day 5, Day 7, Day 14, Day 30, Day 60 and Day 90.
Proportion of patients returning to pre-morbid baseline at 3 months, between treated and untreated groups of patients with WNV infection, as assessed by two scoring systems the Barthel Index and the MRS.
Time Frame: At 3 months.
At 3 months.
Improvement as compared to subject's own worst (of any earlier) evaluation, for each subject as defined by the combined results of the 4 neurological functional tests.
Time Frame: At 3 months.
At 3 months.
Mortality alone among confirmed WNV patients.
Time Frame: At 3 months.
At 3 months.
Combined morbidity and mortality in treatment versus placebo groups for all (including those without WNV infection) subjects by intention to treat analysis.
Time Frame: At 3 months.
At 3 months.
Combined primary endpoint of mortality and morbidity among confirmed WNV patients as assessed by four scoring systems: the Barthel Index, the MRS, the GOS and the 3MS, in the experimental treatment group versus the control group.
Time Frame: At 3 months.
At 3 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2003

Primary Completion (ACTUAL)

December 1, 2006

Study Completion (ACTUAL)

December 1, 2006

Study Registration Dates

First Submitted

September 4, 2003

First Submitted That Met QC Criteria

September 5, 2003

First Posted (ESTIMATE)

September 8, 2003

Study Record Updates

Last Update Posted (ESTIMATE)

February 7, 2011

Last Update Submitted That Met QC Criteria

February 3, 2011

Last Verified

July 1, 2009

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on West Nile Virus

Clinical Trials on Omr-lgG-am

Subscribe